WSJ
09 Nov 2026, 22:50 UTC · 1w ago
A new type of blood thinner approved on Monday is the first shown in testing to prevent repeat strokes without significantly increasing a person's bleeding risk
Impact · against what's priced in
Bayer receives a positive catalyst via the approval of a new blood thinner that prevents repeat strokes without increasing bleeding risk. This provides a structural growth driver for the company's healthcare segment.
- BAYN+0.60
No priced-in read yet





